Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program
Abstract
This proposed rule would codify the Medicare Drug Price Negotiation Program ("Negotiation Program") and would establish certain new policies for the Negotiation Program and the Medicare Prescription Drug Benefit Program as required by the Inflation Reduction Act of 2022. This proposed rule would also propose a modification to the fixed combination drug policy.
Federal Register Source
This document is published by the Office of the Federal Register, National Archives and Records Administration. Access the full regulatory text, preamble, and docket comments below.
View Full Text on FederalRegister.gov →Opens in new tab · federalregister.gov
Other Rules from HHS
Frequently Asked Questions
What is the 2026-12059 Federal Register document?
Document 2026-12059 is a Proposed Rule published by the Department of Health and Human Services in the Federal Register on June 16, 2026. This proposed rule would codify the Medicare Drug Price Negotiation Program ("Negotiation Program") and would establish certain new policies for the Negotiation Program and the Medicare Prescription Drug Benefit Program as required by the Inflation Reduction Act of 2022. This proposed rule would also propose a modification to the fixed combination drug policy. View the original at https://www.federalregister.gov/documents/2026/06/16/2026-12059/medicare-drug-price-negotiation-program-and-medicare-prescription-drug-benefit-program.
Is document 2026-12059 an economically significant rule?
No. Document 2026-12059 is not classified as economically significant under Executive Order 12866. Economically significant rules require OIRA review and are estimated to have impacts of $100 million or more per year.